KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Holly J. Kramer, Raymond R. Townsend, Karen Griffin, Joseph T. Flynn, Daniel E. Weiner, Michael V. Rocco, Michael J. Choi, Matthew R. Weir, Tara I. Chang, Rajiv Agarwal, Srinivasan Beddhu

Research output: Contribution to journalArticle

7 Scopus citations


Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non–dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.

Original languageEnglish (US)
Pages (from-to)437-458
Number of pages22
JournalAmerican Journal of Kidney Diseases
Issue number4
StatePublished - Apr 2019


  • BP control
  • BP measurement
  • BP target
  • Hypertension
  • angiotensin receptor blocker (ARB)
  • angiotensin-converting enzyme inhibitor (ACEi)
  • antihypertensive medication
  • blood pressure (BP)
  • calcium channel blocker (CCB)
  • clinical practice guideline
  • evidence-based medicine
  • kidney disease
  • kidney disease progression
  • nephrology best practices
  • review
  • thiazide diuretic

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline'. Together they form a unique fingerprint.

  • Cite this

    Kramer, H. J., Townsend, R. R., Griffin, K., Flynn, J. T., Weiner, D. E., Rocco, M. V., Choi, M. J., Weir, M. R., Chang, T. I., Agarwal, R., & Beddhu, S. (2019). KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases, 73(4), 437-458. https://doi.org/10.1053/j.ajkd.2019.01.007